What drugs target IL-23 p19 subunit?

8+ drugs target IL-23 p19 subunit, including Mirikizumab - Intravenous (IV), Mirikizumab (MIR), Mirikizumab - SC, Mirikizumab - IV, Risankizumab (RISA).

What drug classes act on IL-23 p19 subunit?

Drug classes acting on IL-23 p19 subunit include IL-23 inhibitor monoclonal antibody, IL-23 inhibitor (monoclonal antibody), IL-23 inhibitor.

IL-23 p19 subunit — Drug Target

8 drugs 6 marketed 2 in Phase 3

All drugs that target IL-23 p19 subunit — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

IL-23 inhibitor monoclonal antibody · IL-23 inhibitor (monoclonal antibody) · IL-23 inhibitor

Marketed (6)

Mirikizumab - Intravenous (IV) · University of North Carolina, Chapel Hill · IL-23 inhibitor monoclonal antibody · Immunology
Mirikizumab is a monoclonal antibody that selectively inhibits interleukin-23 (IL-23) signaling to reduce inflammatory immune responses.
Mirikizumab (MIR) · Alimentiv Inc. · IL-23 inhibitor monoclonal antibody · Immunology / Gastroenterology
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in immune-mediated diseases.
Mirikizumab - SC · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · IL-23 inhibitor monoclonal antibody · Immunology / Gastroenterology
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut.
Mirikizumab - IV · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · IL-23 inhibitor monoclonal antibody · Immunology / Gastroenterology
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut.
Risankizumab (RISA) · Caja Costarricense de Seguro Social · IL-23 inhibitor monoclonal antibody · Immunology
Risankizumab is a monoclonal antibody that selectively inhibits the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.
Ilumya Injectable Product · Psoriasis Treatment Center of Central New Jersey · IL-23 inhibitor (monoclonal antibody) · Immunology/Dermatology
Ilumya (tildrakizumab) is a monoclonal antibody that selectively blocks the IL-23 pathway by binding to the p19 subunit of interleukin-23, reducing inflammatory signaling in psoriasis.

Phase 3 pipeline (2)

risankizumab SC · AbbVie · IL-23 inhibitor (monoclonal antibody) · Immunology
Risankizumab is a monoclonal antibody that selectively blocks the IL-23 cytokine pathway by binding to the p19 subunit of IL-23.
risankizumab IV · AbbVie · IL-23 inhibitor · Immunology
Risankizumab is a humanized monoclonal antibody that selectively binds to and blocks the interleukin-23 (IL-23) p19 subunit.